Watch PPCB. Know when insiders buy.
One email the day a filing lands. Free.
PPCB
Propanc Biopharma, Inc.
0.63
+0.03 +4.74%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4MP/E —DIV YIELD —FCF YIELD -142.53%REV TTM —NET INCOME −$18.9MNET CASH $38K52W 0.60 – 49.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | — | — | — | −$3.5M | −$4.6M | — | -16.67 | −$1.6M | $21 | −$1.6M | Sep 25 |
| Q3 2026 · Mar 31 | — | — | — | −$6.4M | −$6.4M | — | -0.28 | −$1.1M | $154 | −$1.1M | May 14 |
| Q2 2026 · Dec 31 | — | — | — | −$3.7M | −$3.1M | — | -0.30 | −$999K | $2K | −$1M | May 14 |
| Q1 2026 · Sep 30 | — | — | — | −$4.7M | −$4.8M | — | -0.39 | −$1.9M | $2K | −$1.9M | May 14 |
| Q4 2025 · Jun 30derived | — | — | — | −$3.6M | −$4.1M | — | -332.60 | −$92K | — | — | Sep 25 |
| Q3 2025 · Mar 31 | — | — | — | −$53.1M | −$54.1M | — | -12.50 | −$96K | — | — | May 14 |
| Q2 2025 · Dec 31 | — | — | — | −$213K | −$430K | — | -32.23 | $19K | — | — | May 14 |
| Q1 2025 · Sep 30 | — | — | — | −$291K | −$354K | — | -35.97 | −$236K | — | — | May 14 |
| Q4 2024 · Jun 30derived | — | — | — | −$260K | −$359K | — | 1743.88 | −$260K | — | — | Sep 29 |
| Q3 2024 · Mar 31 | — | — | — | −$421K | −$527K | — | -545.79 | −$103K | — | — | May 15 |
| Q2 2024 · Dec 31 | — | — | — | −$438K | −$584K | — | -1559.55 | −$239K | — | — | May 15 |
| Q1 2024 · Sep 30 | — | — | — | −$417K | −$351K | — | -0.04 | −$333K | — | — | May 15 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | — | — | −$18.2M | −$18.9M | — | -17.62 | −$5.7M | $5K | −$5.7M | — | — |
| FY2025 · to Jun 30 | — | — | −$57.3M | −$58.9M | — | -371.22 | −$405K | — | — | — | — |
| FY2024 · to Jun 30 | — | — | −$1.5M | −$1.8M | — | -1420.53 | −$935K | — | — | — | — |
| FY2023 · to Jun 30 | — | — | −$1.8M | −$2.7M | — | -1.80 | −$1.1M | — | — | — | — |
| FY2022 · to Jun 30 | — | — | −$2M | −$2.7M | — | -49.23 | −$1.4M | — | — | — | — |
| FY2021 · to Jun 30 | — | — | −$1.8M | −$2M | — | -0.80 | −$1.1M | — | — | — | — |
Every number comes from Propanc Biopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.